Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The use of Nitric Oxide as a Radiosensitiser of Hypoxic Prostate Cancer Characterized by Data Independent Label-free Ion Mobility LC-MS

ABSTRACT: The use of Nitric Oxide as a Radiosensitiser of Hypoxic Prostate Cancer Characterized by Data Independent Label-free Ion Mobility LC-MS

INSTRUMENT(S): Synapt G2 HDMS

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Permanent Cell Line Cell, Cell Culture

DISEASE(S): Prostate Cancer

SUBMITTER: Hans Vissers

LAB HEAD: Johannes PC Vissers

PROVIDER: PXD009047 | Pride | 2020-02-27

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Publications

The influence of hypoxia on the prostate cancer proteome.

Ross James A JA Vissers Johannes P C JPC Nanda Jyoti J Stewart Grant D GD Husi Holger H Habib Fouad K FK Hammond Dean E DE Gethings Lee A LA

Clinical chemistry and laboratory medicine 20200601 6

Prostate cancer accounts for around 15% of male deaths in Western Europe and is the second leading cause of cancer death in men after lung cancer. Mounting evidence suggests that prostate cancer deposits exist within a hypoxic environment and this contributes to radio-resistance thus hampering one of the major therapies for this cancer. Recent reports have shown that nitric oxide (NO) donating non-steroidal anti-inflammatory drugs (NSAIDs) reduced tumour hypoxia as well as maintaining a radio-se ...[more]

PMID: 31940282

Similar Datasets

LC-MSMS analysis of human urine to identify early diagnostic biomarkers for prostate cancer

Project description:In order to detect proteins sensitive and specific enough to detect early stages of PCa, we performed a complex comparative proteomic study analyzing urine as a source for non-invasive biomarkers. We compared urine samples from patients with early PCa stages and Gleason score between 6 and 7 with samples from patients with BPH and other urological cancers, namely bladder and renal. The main goal of this study was to discover a diagnostic biomarker or set of biomarkers in urine, sufficiently sensitive to detect PCa in its early stages and specific enough to separate the disease from BPH or other urological cancers.

2018-01-02 | PXD008407 | Pride

Non-labelled proteomics expression analysis of PC-3 cells treated with transferrin conjugated gold nanoparticles

Project description:Nanoparticles-based therapeutics are being clinically translated for treating cancer. Meanwhile nanoparticles are increasingly being identified as impacting cell regulation and protein expression. Here, we sought to understand how a model of a relatively inert nanoparticle without any therapeutic agent itself interact with the cells and what are the key biological mechanisms.

2023-10-24 | PXD039433 | Pride

Detection of Aggressive Prostate Cancer-Associated Glycoproteins in Urine using Glycoproteomics and Mass Spectrometry

Project description:Clinical management of prostate cancer remains a significant challenge due to the lack of available tests for guiding treatment decisions. The blood Prostate-Specific Antigen (PSA) test has facilitated early detection and intervention of prostate cancer. However, blood PSA levels are less effective in distinguishing aggressive from indolent prostate cancers and other benign prostatic diseases. Thus, the development of novel approaches specific for prostate cancer that can differentiate aggressive from indolent disease remains an urgent medical need. In the current study, we evaluated urine specimens from prostate cancer patients instead of serum using liquid chromatography-tandem mass spectrometry (LC-MS/MS), with the aim of identifying effective prostate cancer biomarkers. Glycoproteins from urine samples of prostate cancer patients with different Gleason scores were characterized via solid phase extraction of N-linked glycosite-containing peptides and LC-MS/MS. In total, 2923 unique glycosite-containing peptides were identified. Comparison of urine-based glycoproteins with those identified from aggressive and non-aggressive prostate cancer tissues as well as sera from prostate cancer patients revealed that the majority of aggressive prostate cancer-associated glycoproteins were more readily detected in patient urine than serum samples. Our data collectively indicate that urine provides a highly reliable source for biomarker testing in patients with aggressive prostate cancer.

2022-02-28 | PXD004495 | Pride

Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failure

Project description:Twenty-one patients with locally advanced squamous cell carcinoma were enrolled in this study. Primary biopsies harvested prior to therapy were divided according to the patientM-bM-^@M-^Ys 6 months clinical response and analyzed for whole human gene expression (Agilent). A 2859-gene signature was identified to distinguish between responder and non-responder patients. M-bM-^@M-^XDNA Replication, Recombination and RepairM-bM-^@M-^Y represented one of the most important mechanisms activated in non-responsive cervical tumors, and M-bM-^@M-^XRole of BRCA1 in DNA Damage ResponseM-bM-^@M-^Y was predicted to be the most significantly altered canonical pathway involved in intrinsic resistance. The microarray results were validated by qRT-PCR and immunohistochemistry. An additional set of 24 formalin-fixed paraffin-embedded cervical cancer samples was used for independent validation of the proteins of interest. Immunohistological staining confirmed increased expression of BRCA1, BRIP1, FANCD2 and RAD51 in non-responsive compared with responsive advanced squamous cervical cancer, both in the initial set of 21 cervical cancer samples and the second set of 24 samples. Twenty-one patients with locally advanced squamous cell carcinoma (FIGO stage IIB-IIIB) were enrolled in the genomics study. A tissue fragment from a primary biopsy specimen was harvested from each patient prior to the therapy. Tissue samples were stored in liquid nitrogen until use for RNA extraction. One-color microarray experiment was performed to measure differences in gene expression between cervical cancer samples with 6-month complete response (12 patients ) and non-complete response (9 patients). Complet response group was considered as reference.

2014-03-31 | E-GEOD-56363 | biostudies-arrayexpress

Transcription profiling of blood from patients with HNSCC who either responded to radiotherapy with a high or low increase in plasma DROM and decrease in FRAP

Project description:The study was performed on a subgroup of a larger study including 78 patients with histologically verified HNSCC recruited from Division of Cancer Medicine and Radiotherapy, Norwegian Radium Hospital, Rikshospitalet University Hospital in the period from May 2003 to May 2006. The patients received either post-operative radiotherapy or radiotherapy alone for a period of 5-7 weeks.<br>Ten HNSCC patients, responding to radiotherapy with a high relative increase in plasma DROM and high decrease in FRAP (responder), were compared to ten patients with low increase in DROM and low decrease in FRAP (non responder). Microarray analysis of full blood were performed on pre and post radiotherapy samples.<br>

2010-10-31 | E-MEXP-2460 | biostudies-arrayexpress

LNCaP Atlas: Gene expression associated with in vivo progression to castration-recurrent prostate cancer

Project description:Background: There is no cure for castration-recurrent prostate cancer (CRPC) and the mechanisms underlying this stage of the disease are unknown. Methods: We analyzed the transcriptome of human LNCaP prostate cancer cells as they progress to CRPC in vivo using replicate LongSAGE libraries. We refer to these libraries as the LNCaP atlas and compared these gene expression profiles with current suggested models of CRPC. Results: Three million tags were sequenced using in vivo samples at various stages of hormonal progression to reveal 96 novel genes differentially expressed in CRPC. Thirty-one genes encode proteins that are either secreted or are located at the plasma membrane, 21 genes changed levels of expression in response to androgen, and 8 genes have enriched expression in the prostate. Expression of 26, 6, 12, and 15 genes have previously been linked to prostate cancer, Gleason grade, progression, and metastasis, respectively. Expression profiles of genes in CRPC support a role for the transcriptional activity of the androgen receptor (CCNH, CUEDC2, FLNA, PSMA7), steroid synthesis and metabolism (DHCR24, DHRS7, ELOVL5, HSD17B4, OPRK1), neuroendocrine (ENO2, MAOA, OPRK1, S100A10, TRPM8), and proliferation (GAS5, GNB2L1, MT-ND3, NKX3-1, PCGEM1, PTGFR, STEAP1, TMEM30A), but neither supported nor discounted a role for cell survival genes. Conclusions: The in vivo gene expression atlas for LNCaP was sequenced and support a role for the androgen receptor in CRPC. BMC Medical Genomics 2010, 3:43 RNA from the hollow fibres of three mice (biological replicates) representing different stages of prostate cancer progression (AS, RAD, and CR) were used to make a total of nine LongSAGE libraries.

2010-09-26 | E-GEOD-18402 | biostudies-arrayexpress

Strategies to enable large-scale proteomics for reproducible research.

Project description:An experiment was designed to assess the reproducibility of SWATH-MS measurements collected from different mass spectrometers in a single facility over a period spanning approximately four months. Data were acquired with 90-minute gradient lengths at the Australian Cancer Research Foundation International Centre for the Proteome of Human Cancer (ProCan) on six SCIEX TripleTOF 6600 QTOF mass spectrometers. Multiple replicate aliquots were prepared for eight samples. These comprised a dilution series of ovarian cancer tissue (0%, 3.125%, 6.25%, 12.5%, 25% and 50%) offset by yeast and a fixed proportion (50%) of prostate cancer tissue (Samples 1-6), a 1:1 mix of ovarian cancer tissue and yeast cells (Sample 7), and a human cell line (HEK293T; Sample 8). On each mass spectrometer, sets of 20 replicate aliquots (three aliquots of Samples 2-5, and two aliquots of Samples 1, 6-8) were run during each of thirteen 48-hour periods. Experimental data were acquired in 48-hour time periods on each instrument continuously for eight days (with sets of 20 replicates commencing on days 1, 3, 5 and 7), once per week for the remainder of the month (commencing on days 14, 21 and 28), and then once per month for the remainder of the first three months (commencing on days 56 and 84). After each instrument underwent a major clean, the sets of 20 replicates were again run continuously for a further eight days (commencing on days 101, 103, 105 and 107). Data were therefore acquired during a total of thirteen 48-hour periods over approximately four months, during which time the mass spectrometry facility was fully operational. Mass spectrometer maintenance schedules varied according to each individual instrument's performance, and each instrument commenced data acquisition asynchronously within 28 days from the experiment start.

2020-07-20 | PXD015912 | Pride

Transcription profiling of high and low grade gliomas from human patients to identify new diagnostic and prognostic markers

Project description:Comparison of high grade to low grade gliomas.

2007-06-01 | E-TABM-167 | biostudies-arrayexpress

Genome-wide analysis of matched microRNA-mRNA time-course data after androgen injection to prostate cancer LNCaP cell line

Project description:Androgen receptor (AR) signalling pathway plays an important role in carcinogenesis and development of prostate cancer. The involvement of microRNA (miRNA) in this process is still largely unknown. In this study, we performed a matched miRNA-mRNA time-course expression profiling to reveal androgen response in hormone-sensitive prostate cancer cells.We introduced novel statistics Response Score (RS) and Modulation Score (MS) to identify significant androgen-regulated target genes and miRNA-modulated target mRNAs. Based on the analysis, we found several novel androgen-regulated targets, which had significant androgen response in expression pattern, and were highly enriched in predicted androgen responsive elements (AREs). AR-bindings to these AREs were validated with ChIP assay. Furthermore, a set of target mRNAs involved in crucial processes of tumor progression were identified to be significantly regulated by these miRNAs. Therefore, a miRNA-mediated androgen signalling network was inferred, including three novel feedback mechanisms for AR self-modulation. In conclusion, our study provides new approaches to further miRNA regulation research and contributes novel findings into miRNA-mediated pathological effects in prostate cancer. Total RNA obtained from androgen dihydrotestosterone (DHT) subjected to LNCaP cells in vitro at 20min, 40min, 1h, 2h, 4h, 8h, 16h, 24h and 48h, compared to the control at 0h.

2011-12-31 | E-GEOD-21245 | biostudies-arrayexpress

Staphylococcal Nuclease and Tudor Domain Containing protein SND1 interacts with ERG and plays a critical role in prostate cancer in vivo

Project description:ERG is a transcriptional factor, which is recombined with promoter of TMPRSS2 and prominently overexpressed in half of human prostate cancers. The mechanisms of ERG-mediated oncogenesis are not completely understood. We performed an unbiased Mass Spectrometry screen for ERG-binding proteins and found that ERG binds to MTDH/SND1 protein complex in prostate cancer cells. We determined that ERG binds to the SND1/MTDH protein complex via SND1 and this interaction plays a critical role in ERG-mediated cancer.

2023-03-22 | PXD036882 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data